Chief medical officer jumps ship in wake of bluebird trial stoppage

17 March 2021
bluebird_bio_large

In a  filing with the US Securities and Exchange Commission (SEC), bluebird bio (Nasdaq: BLUE) has announced the departure of its chief medical officer, David Davidson.

The company said Dr Davidson would continue to be engaged as a consultant, “for a period of six months,” in order to provide “ongoing guidance and support for bluebird’s late-stage development programs in severe genetic disease.”

The Boston-based firm saw its shares tumble in February, after a suspected serious adverse reaction put a stop to trials into an experimental LentiGlobin gene therapy for sickle cell disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology